Skip to main content
Clinical Trials/NCT00966199
NCT00966199
Unknown
Phase 4

Medication Induced Blood Pressure Reduction; Assessment of Cerebral Perfusion and Cognition in Hypertensive Elderly

Radboud University Medical Center1 site in 1 country60 target enrollmentSeptember 2009

Overview

Phase
Phase 4
Intervention
anti-hypertensive medication
Conditions
Hypertension
Sponsor
Radboud University Medical Center
Enrollment
60
Locations
1
Primary Endpoint
Cerebral blood flow
Last Updated
16 years ago

Overview

Brief Summary

The purpose of this study is to determine if a reduction in systolic blood pressure induced by anti-hypertensive medication results in changes in cerebral perfusion and cognition in hypertensive elderly. Hypertensive elderly will be treated using open-label anti-hypertensive medication for 8-12 weeks. Changes in cerebral perfusion and cognition will be assessed before and after treatment.

Registry
clinicaltrials.gov
Start Date
September 2009
End Date
December 2013
Last Updated
16 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Age \>= 70 years
  • Systolic office blood pressure \>= 160 mmHg
  • Systolic home blood pressure \>= 155 mmHg

Exclusion Criteria

  • Diabetes Mellitus
  • Atrial fibrillation
  • Renal failure requiring dialysis
  • Life expectancy of less than 1 year
  • Disabling stroke
  • Contraindication for MRI or anti-hypertensive medication
  • Systolic blood pressure \> 220 mmHg

Arms & Interventions

Hypertensive elderly

community dwelling hypertensive elderly from general practices

Intervention: anti-hypertensive medication

Outcomes

Primary Outcomes

Cerebral blood flow

Time Frame: T1, 8-12 weeks of treatment, T2

Secondary Outcomes

  • Cognitive functioning assessed by neuropsychological testing(T1, 8-12 weeks of treatment, T2-3)

Study Sites (1)

Loading locations...

Similar Trials